Telix Pharmaceuticals (ASX:TLX) has taken another step in its push to bring novel radiopharmaceutical therapies to men with advanced prostate cancer, confirming that the first patient has now been treated in the randomised expansion phase of its pivotal ProstACT Global Phase 3 trial. …
Telix doses first patient in expanded Phase 3 prostate cancer trial
December 8, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
The Dispatched Podcast 'Week in Review' - 20 February
February 20, 2026 - - Podcast -
PhRMA launches new campaign against the backdrop of a more assertive U.S.
February 19, 2026 - - Latest News -
Why does anyone accept a review outcome that simply affirms a settled order
February 19, 2026 - - Latest News -
Wesfarmers Health emerges as growth engine after delivering strong first half
February 19, 2026 - - Australian Biotech -
Telix files for European approval of brain cancer imaging candidate TLX101-Px
February 18, 2026 - - Australian Biotech -
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 - - Latest News -
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 - - Australian Biotech